Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-interleukin 6: first line in rheumatoid arthritis?

× No keyword cloud information.

14 in total

1. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Authors: R N Maini; P C Taylor; J Szechinski; K Pavelka; J Bröll; G Balint; P Emery; F Raemen; J Petersen; J Smolen; D Thomson; T Kishimoto
Journal: Arthritis Rheum Date: 2006-09

2. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.

Authors: K Owczarczyk; M Hellmann; G Fliedner; T Röhrs; K Maizus; D Passon; M Hallek; A Rubbert
Journal: Ann Rheum Dis Date: 2008-11 Impact factor: 19.103

3. Inhibiting interleukin-6 in rheumatoid arthritis.

Authors: Ernest Choy
Journal: Curr Rheumatol Rep Date: 2008-10 Impact factor: 4.592

4. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.

Authors: Minoru Fujimoto; Satoshi Serada; Masahiko Mihara; Yasushi Uchiyama; Hiroto Yoshida; Nobuo Koike; Yoshiyuki Ohsugi; Teppei Nishikawa; Barry Ripley; Akihiro Kimura; Tadamitsu Kishimoto; Tetsuji Naka
Journal: Arthritis Rheum Date: 2008-12

5. Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil.

Authors: Morton Scheinberg; José Goldenberg; Daniel P Feldman; João Luiz Nóbrega
Journal: Clin Rheumatol Date: 2008-05-08 Impact factor: 2.980

Review 6. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal.

Authors: Roberto Caporali; Francesca Bobbio Pallavicini; Matteo Filippini; Roberto Gorla; Antonio Marchesoni; Ennio Giulio Favalli; Piercarlo Sarzi-Puttini; Fabiola Atzeni; Carlomaurizio Montecucco
Journal: Autoimmun Rev Date: 2008-11-17 Impact factor: 9.754

7. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.

Authors: Keiichi Iwanami; Isao Matsumoto; Yoko Tanaka-Watanabe; Asuka Inoue; Masahiko Mihara; Yoshiyuki Ohsugi; Mizuko Mamura; Daisuke Goto; Satoshi Ito; Akito Tsutsumi; Tadamitsu Kishimoto; Takayuki Sumida
Journal: Arthritis Rheum Date: 2008-03

8. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors: N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal: Ann Rheum Dis Date: 2008-11-19 Impact factor: 19.103

Review 9. Abatacept in the treatment of rheumatoid arthritis.

Authors: Maya H Buch; Edward M Vital; Paul Emery
Journal: Arthritis Res Ther Date: 2008-10-15 Impact factor: 5.156

10. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors: P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal: Ann Rheum Dis Date: 2008-07-14 Impact factor: 19.103